亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial

克洛巴扎姆 医学 儿科 随机对照试验 奥卡西平 不利影响 麻醉 人口 癫痫 精神科 内科学 卡马西平 环境卫生
作者
Marleen M L van Arnhem,Bart van den Munckhof,Alexis Arzimanoglou,Emilio Perucca,Liisa Metsähonkala,Guido Rubboli,Marianne Søndergaard Khinchi,Anne de Saint Martin,Kerstin Alexandra Klotz,Julia Jacobs,J. Helen Cross,Irene Morales,Wim Otte,Heleen C. van Teeseling,Frans S.S. Leijten,Kees P. J. Braun,Floor E. Jansen,Anna Jansen,Lieven Lagae,Thomas Bast
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:23 (2): 147-156 被引量:8
标识
DOI:10.1016/s1474-4422(23)00409-x
摘要

Background Epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) is a rare syndrome associated with cognitive and behavioural regression. On the basis of mostly small observational and retrospective studies, corticosteroids and clobazam are often considered the most effective treatments for this syndrome. We aimed to compare cognitive outcomes of children with EE-SWAS 6 months after starting treatment with either corticosteroids or clobazam. Methods We did a multicentre, randomised controlled trial at eight tertiary referral centres for rare epilepsies in seven European countries. Children were eligible to participate if they were aged 2–12 years, were diagnosed with EE-SWAS within 6 months before inclusion, and had not been treated with corticosteroids or clobazam previously. Participants were randomly assigned (1:1) to treatment with corticosteroids (either continuous treatment with 1–2 mg/kg per day of prednisolone orally or pulse treatment with 20 mg/kg per day of methylprednisolone intravenously for 3 days every 4 weeks) or clobazam (0·5–1·2 mg/kg per day orally). The primary outcome was cognitive functioning after 6 months of treatment, which was assessed by either the intelligence quotient (IQ) responder rate (defined as improvement of ≥11·25 IQ points) or the cognitive sum score responder rate (defined as improvement of ≥0·75 points). Safety was assessed by number of adverse events and serious adverse events. Data were analysed in the intention-to-treat population, which included all children as randomised who had primary outcome data available at 6 months. The trial is registered with the Dutch Trial Register, Toetsingonline, NL43510.041.13, and the ISRCTN registry, ISRCTN42686094. The trial was terminated prematurely because enrolment of the predefined number of 130 participants was deemed not feasible. Findings Between July 22, 2014, and Sept 3, 2022, 45 children were randomly assigned to either corticosteroids (n=22) or clobazam (n=23); two children assigned clobazam dropped out before 6 months and were excluded from the intention-to-treat analysis. At the 6-month assessment, an improvement of 11·25 IQ points or greater was reported for five (25%) of 20 children assigned corticosteroids versus zero (0%) of 18 assigned clobazam (risk ratio [RR] 10·0, 95% CI 1·2–1310·4; p=0·025). An improvement of 0·75 points or more in the cognitive sum score was recorded for one (5%) of 22 children assigned corticosteroids versus one (5%) of 21 children assigned clobazam (RR 1·0, 95% CI 0·1–11·7, p=0·97). Adverse events occurred in ten (45%) of 22 children who received corticosteroids, most frequently weight gain, and in 11 (52%) of 21 children who received clobazam, most often fatigue and behavioural disturbances. Occurrence of adverse events did not differ between groups (RR 0·8, 95% CI 0·4–1·4; p=0·65). Serious adverse events occurred in one child in the corticosteroid group (hospitalisation due to laryngitis) and in two children in the clobazam group (hospitalisation due to seizure aggravation, and respiratory tract infection). No deaths were reported. Interpretation The trial was terminated prematurely, and the target sample size was not met, so our findings must be interpreted with caution. Our data indicated an improvement in IQ outcomes with corticosteroids compared with clobazam treatment, but no difference was seen in cognitive sum score. Our findings strengthen those from previous uncontrolled studies that support the early use of corticosteroids for children with EE-SWAS. Funding EpilepsieNL, WKZ fund, European Clinical Research Infrastructure Network, and Ming fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xxx完成签到,获得积分10
2秒前
8秒前
Green完成签到,获得积分10
10秒前
斐嘿嘿发布了新的文献求助10
11秒前
谢丹完成签到 ,获得积分10
12秒前
寒冷的完成签到,获得积分10
16秒前
文武完成签到 ,获得积分10
20秒前
zlf完成签到,获得积分10
21秒前
43秒前
43秒前
香蕉觅云应助科研通管家采纳,获得10
43秒前
57秒前
林宥嘉完成签到 ,获得积分10
1分钟前
老夫子完成签到,获得积分10
1分钟前
kenti2023完成签到 ,获得积分10
1分钟前
1分钟前
YYYCCCCC发布了新的文献求助10
1分钟前
1分钟前
11发布了新的文献求助10
1分钟前
CipherSage应助miles采纳,获得10
1分钟前
周游完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
huihongzeng发布了新的文献求助10
1分钟前
Judy完成签到 ,获得积分10
1分钟前
利物鸟贝拉完成签到,获得积分10
1分钟前
1分钟前
Esperanza完成签到,获得积分10
1分钟前
miles发布了新的文献求助10
2分钟前
2分钟前
鹿茸与共发布了新的文献求助10
2分钟前
2分钟前
jianghs完成签到,获得积分10
2分钟前
科目三应助11采纳,获得10
2分钟前
jianghs发布了新的文献求助10
2分钟前
2分钟前
feifei完成签到,获得积分10
2分钟前
feifei发布了新的文献求助10
2分钟前
福娃哇完成签到 ,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990015
求助须知:如何正确求助?哪些是违规求助? 3532077
关于积分的说明 11256227
捐赠科研通 3270933
什么是DOI,文献DOI怎么找? 1805139
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228